ARTICLE | Clinical News
OPHD001: Began Phase II testing
June 14, 1999 7:00 AM UTC
Ophidian Pharmaceuticals Inc. (OPHD), Madison, Wis. Product: OPHD001 Business: Autoimmune/Inflammation Therapeutic category: Antibody Target: Clostridium difficile Description: Avian antibody against ...